Objective: To characterize the frequency of and risk factors for out-of-hospital sudden neurologic deaths.
Sudden cardiac death (SCD) is defined as a sudden unexpected death occurring within 1 hour of symptom onset for witnessed events, or within 24 hours of being observed symptom-free for unwitnessed events. 1 By this definition, there are 184,000 to 450,000 sudden cardiac deaths in the United States annually and more than 90% occur out of the hospital. 2 Since complete autopsies are uncommon and investigations for these natural deaths are limited, a cardiac cause is often assumed and cerebrovascular deaths or sudden unexpected death in epilepsy (SUDEP) could be missed. Therefore, we conducted complete autopsies and systematically evaluated consecutive out-of-hospital SCDs as part of the Postmortem Systematic Investigation of Sudden Cardiac Death (POST SCD) Study. 3 METHODS From February 2011 to March 2013, through active, real-time surveillance of all medical examiner cases, we identified all incident SCDs within the city and county of San Francisco. 3 State law mandates reporting all out-of-hospital deaths to the medical examiner. 1 All cases were referred for systematic and comprehensive evaluations, including full autopsies, toxicology, and detailed heart and cranial vault examinations. A multidisciplinary committee of cardiologists and cardiac electrophysiologists, anatomic and forensic pathologists, and a neurologist adjudicated the causes of death by consensus. Stata (StataCorp LP, College Station, TX) was used for all statistical analyses.
Standard protocol approvals, registrations, and patient consents. Local institutional review board approval with a waiver of informed consent was obtained for this study.
RESULTS
Of 352 consecutive SCDs identified during the 25-month study period, 335 (95.2%) underwent a systematic evaluation and full autopsy (table 1) . Of these 335 cases, 18 (5.4%) had an acute neurologic cause of death (table 2) . Sudden neurologic death accounted for 15% (18 of 121) of all noncardiac deaths, and was the most common noncardiac cause of sudden death after drug overdose. The risk of sudden neurologic death compared to non-neurologic sudden cardiac death was lower in male (p 5 0.001) and white participants (p 5 0.01). Sudden neurologic deaths were typically unwitnessed (16; 89% vs 74%; p 5 0.26) and had asystole at initial presentation (15; 83% vs 79%; p 5 0.14).
Most intracerebral (6/8) and subarachnoid (1/2) hemorrhage deaths occurred while on antiplatelet or Table 1 Characteristics of sudden cardiac deaths (SCD), sudden neurologic deaths (SND), non-neurologic sudden deaths, and adult San Francisco population All SCD SCD non-neurologic SND ) . Of the 6 SUDEP cases, 3 had nonspecific cardiac findings (minor thickening of septal and posterior left ventricle and interstitial fibrosis) and 1 case had a witnessed seizure followed by asystole and apnea. Two cases were in young women with juvenile myoclonic epilepsy, including 1 who had recently stopped taking seizure medications. SUDEP cases were significantly younger than other sudden neurologic deaths and the cohort overall (mean age 45 years; SD 14.8; range 27-67; p 5 0.001 and p 5 0.002, respectively).
A history of epilepsy was identified in 15 of 335 (4.5%) sudden deaths; 6 (40%) were SUDEP. Of the remaining 9 sudden deaths in epilepsy patients, 7 died of cardiac causes (2 hypertrophy, 2 cardiomyopathy, 1 chronic coronary artery disease, 1 acute coronary artery disease, 1 heart failure) and 2 had noncardiac deaths (1 intracranial hemorrhage, 1 incarcerated hernia). A history of epilepsy was associated with a substantially higher relative risk of sudden neurologic death compared to sudden cardiac death (relative risk 10.6, 95% CI 4.6-25.5; p , 0.0001). Similarly, 7.5% (25 of 335) sudden deaths had a history of at least 1 seizure, often in the setting of alcohol withdrawal; 24% (6 of 25) were SUDEP. For the 10 cases with history of seizure but not epilepsy, 5 died of cardiac causes, 1 had a pulmonary embolism, 1 had hemorrhage, and 3 had an overdose. DISCUSSION In this comprehensive, populationbased study of consecutive out-of-hospital apparent SCDs, 5.4% were due to an acute neurologic cause. These sudden neurologic deaths represented the largest group of noncardiac sudden deaths after drug overdose. The lower risk of sudden neurologic death compared to sudden cardiac death among male and white participants and a corresponding trend toward increased risks in women and the fast-growing population of Asians and Hispanics may justify follow-up studies to evaluate whether greater vigilance is warranted for specific demographics. Prior estimates of out-of-hospital sudden death were derived from ethnically homogeneous populations with low autopsy rates (typically ,15%) or were based on retrospective review of records from incomplete or selectively applied investigations. 4 Moreover, in the rare cases when they are performed, autopsies for natural out-of-hospital deaths often exclude cranial vault or neuropathologic examination, thereby increasing the risk for misclassification. 5, 6 Given that the case fatality rate for stroke is high, cerebrovascular deaths were not unexpected. Although stroke can cause death through direct mass effect, hydrocephalus, and herniation, especially when unwitnessed and untreated, neurocardiogenic pathways can also be involved. For instance, subarachnoid hemorrhage can cause characteristic electrocardiographic changes and a Takotsubo pattern of apical hypokinesis and cardiac injury (voodoo death) and increased intracranial pressure can cause autonomic changes and arrhythmias. 7 For SUDEP, the mechanism of death may also include neurocardiogenic and neurorespiratory mechanisms.
Assuming that 5.4% of apparent SCDs are sudden neurologic deaths, as we found, then there are 10,000 to 25,000 sudden neurologic deaths in the United States annually. 2 Similarly, if half of the 2.3% of intracerebral hemorrhage deaths we observed were missed without a full autopsy, this would translate into 2,000 to 5,000 fatal intracerebral hemorrhages annually (a 30% increase in incidence). 8 For aneurysmal subarachnoid hemorrhage, similar assumptions would result in an additional 500 to 1,300 fatal subarachnoid hemorrhages annually (a nearly 25% increase in incidence). 9 For SUDEP, assuming a 1% prevalence of epilepsy among San Francisco adult population of 725,225, the 3.4 out-of-hospital cases per year we observed represents about half of the expected SUDEP cases, though our methods only capture out-of-hospital deaths. 10 A failure to identify sudden neurologic deaths, particularly among those at high risk for SCD, has potential implications for interpreting the results in large cardiovascular trials. Those at high risk for SCD are often on antithrombotic therapy, which increases the risk of hemorrhage. Yet identifying intracerebral hemorrhage adverse outcomes among these clinical trial participants typically relies on the overburdened medical examiner and coroner's infrastructure, low prevailing autopsy rates, and unreliable death certificates. Although the limited number of outcomes in our study precludes a precise characterization of associated risk factors, overall misclassification of these outcomes in cardiovascular clinical trials could shift balance of the relative risks and benefits of antithrombotic therapy.
Sudden neurologic death accounts for a substantial proportion of sudden deaths that would otherwise meet the widely applied epidemiologic definition of out-of-hospital SCD. Systematic autopsies of nearly every SCD in San Francisco over a 2-year period allowed for the accurate recognition of these neurologic causes and provide a framework for revising estimates of the incidence of acutely fatal neurologic events. These data may change public health estimates of disease burden and mortality attributed to SCD and to neurologic disorders in the general population, for women and certain race-ethnic subgroups in particular, and among high-risk participants in cardiovascular clinical trials.
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